Good Company

Gamgee Is Trying to Turn One Dog's Cancer Vaccine Into a Treatment Any Oncologist Can Order

A founder taught himself genomics to save his dog Rosie. Now his San Francisco startup, backed by $4 million from Founders Fund and a Y Combinator slot, has to prove a viral single case can become a repeatable clinical product.

By Good Company Editorial Desk

Gamgee logo

The News

Most pet companies start with a market. Gamgee started with one dog.

Rosie was an eight year old Staffordshire bull terrier cross, a rescue dog living in Sydney, Australia, when she was diagnosed with mast cell cancer in May 2024. Mast cell tumors are the most common skin cancer in dogs. In Rosie's case, surgery slowed the disease without stopping it, and chemotherapy and immunotherapy failed as well. Her owner, Paul Conyngham, was told she had months to live.

Conyngham had 17 years of experience in machine learning and no training in biology. What he did next is Gamgee's founding story: over two years, he taught himself genomics and bioinformatics, paid about $3,000 to have her tumor DNA and healthy DNA sequenced at the University of New South Wales, and used AI tools, including ChatGPT and AlphaFold, to sift thousands of mutations for neoantigens, the mutated proteins that appear only on cancer cells and can flag those cells for the immune system. Researchers at UNSW reviewed the data and built the actual mRNA vaccine in a university lab, with Dr. Pall Thordarson, director of the UNSW RNA Institute, leading that work. Reporting says Australian ethics approval alone took three months and a 100 page document.

Rosie received her first injection in December 2025 at a veterinary facility in Queensland, with a booster the following month. Several of her tumors shrank significantly. The Y Combinator listing for the company that followed describes the treatment as what is believed to be the first fully computationally designed mRNA cancer vaccine ever delivered to a dog. Gamgee's own site cites a tumor reduction of roughly 75 percent in that case, and carries the caveat itself that the figure comes from a single case and may vary. In March 2026 the story went viral, and OpenAI chief executive Sam Altman shared it with his millions of followers.

Then comes the part the viral version mostly skipped, and to its credit, Gamgee's own launch announcement does not skip it: Rosie entered remission, but her cancer returned following a later surgery. The launch release is titled around her legacy and writes about her in the past tense. The company has not publicly stated what ultimately happened to her or when.

What launched on August 17, 2026 is the attempt to turn that one off effort into a system. Gamgee, which lists San Francisco as its headquarters in its Y Combinator profile and joined Y Combinator's Summer 2026 batch, announced a $4 million seed round led by Founders Fund. The round also drew Celine Halioua, founder and CEO of Loyal, Steve Eidelman, founder of Modern Animal, Arash Ferdowsi, co-founder of Dropbox, and Gokul Rajaram, creator of Google AdSense. A pet longevity founder and a veterinary clinic founder writing checks alongside two Silicon Valley operators is exactly the bridge this company has to cross, from a technology story into a veterinary product.

The product, as the company describes it, industrializes each step Conyngham did by hand. Gamgee sequences a dog's tumor and matched healthy tissue, uses AI to identify the tumor specific neoantigens, designs a personalized mRNA vaccine encoding those targets, and manages the full chain from veterinary intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring. The company says a finished vaccine can be delivered in about four weeks, a timeline drawn from Rosie's case, and pitches the workflow to veterinarians as requiring little added chair time per case. Pricing has not been publicly disclosed.

Clinical studies are now underway in Australia, in collaboration with UNSW, the University of Queensland and the Garvan Institute of Medical Research. The company says it has established and validated its treatment protocol with those partners. Enrollment is limited to eastern Australia, trial dogs receive the investigational vaccine at no cost, and eligibility is set by the study protocol and participating veterinary oncologists. For the United States, the company says it is working with regulators to establish the appropriate USDA pathway for a patient specific veterinary biologic. That agency detail matters: animal vaccines in the US are regulated by the USDA's Center for Veterinary Biologics, not the FDA.

"When Rosie was diagnosed, I taught myself genomics and bioinformatics because no other path existed. We crossed disciplines, worked alongside world-class researchers, and designed her personalized vaccine. Every dog deserves the same chance Rosie had," Conyngham said in the launch announcement.

The company's stated ambition reaches well past one product. Gamgee says its long term aim is to make personalized mRNA vaccines deliverable through any veterinary oncologist, and to establish N-of-1 medicine, treatment designed for a single patient, as a fundamentally better model of treatment across species, humans included.

Why It Matters

Start with the size of the problem. Cancer is the leading cause of death in dogs, according to Gamgee's launch announcement, and figures long cited by the American Veterinary Medical Association and the Veterinary Cancer Society estimate that about one in four dogs will develop cancer in their lifetime, rising to almost half of dogs over age 10. The company also notes that more than 1,600 oncology therapeutics and vaccines are in development worldwide. Veterinary oncology is a large market where the standard options, surgery, chemotherapy and radiation, are blunt instruments, and owners have repeatedly shown they will pay for advanced care when a credible option exists.

Gamgee's real claim to difference is specificity. Personalized cancer treatment for dogs is not new. Torigen, which spun out of Notre Dame in 2017, has treated roughly 2,000 animals with an autologous vaccine made from a patient's own excised tumor tissue. ELIAS Animal Health holds USDA approval for a personalized vaccine plus T cell therapy for canine osteosarcoma. Boehringer Ingelheim's Oncept is a DNA vaccine for canine melanoma. What none of those approaches does is sequence a tumor's genome and design a vaccine around that one tumor's specific mutations. That is the step Rosie's case demonstrated, and it mirrors where human oncology is heading: personalized neoantigen mRNA vaccines have been in human development for more than a decade, and Moderna and Merck's candidate cut the risk of melanoma recurrence or death by 44 percent in a randomized trial, according to Merck's 2022 announcement. Gamgee is asking whether the most advanced idea in human cancer immunotherapy can be rebuilt, cheaper and faster, for dogs first.

Now the hard part, because this company will be covered everywhere as an AI miracle and the record does not support that yet. Rosie is one dog. There was no control group and no comparison animal. She received the vaccine alongside other treatments, so there is no way to separate the vaccine's effect from surgery, chemotherapy, immunotherapy or the natural variability of an individual tumor, and mast cell tumors are known to behave unpredictably. Key clinical details, including the grade of her tumor, one of the strongest predictors of outcome in mast cell disease, have not been made public. Her cancer also came back. None of that makes the case worthless: a hypothesis generating case is how a field starts. It does mean the case is a starting gun, not a result.

The specialists quoted in coverage of the case make the same point in plainer language. "We cannot be sure how much of Rosie's improvement is due to the vaccine, how long it will last, or whether the same approach would help other dogs," veterinary oncologist Justin Stebbing wrote in The Conversation. Ashley Kalinauskas, CEO of Torigen, told R&D World: "It's super cool, but I think that it's going to be a challenge to really understand how that could be applied to your everyday dog patient."

That is why the Australian studies, not the origin story, are the company now. Gamgee's own scientific partner frames the trial question as a delivery and consistency question, not a miracle question. "Sometimes the best thing to do is ask 'why not', why not use the biology of an individual dog's tumor to design its treatment? This study is designed to test whether this personalized approach can be delivered safely, and done consistently, in a clinical setting. The intersection of genomics, AI, and RNA technology is ripe for exactly this kind of work," said Dr. Paul Thordarson, director of the UNSW RNA Institute, in the launch announcement.

There is one more reason this small company matters. Gamgee is part of a clear 2026 pattern: pet venture money moving into biology, into drugs and diagnostics built on genomic evidence rather than apps and devices. If N-of-1 manufacturing can be made routine in veterinary medicine, where the USDA path is shorter and cheaper than a human drug program, dogs become the proving ground for a model human medicine is still struggling to scale. Founders Fund partner Amin Mirzadegan said in the announcement: "Paul's love for Rosie led him to cross disciplines, teach himself entirely new fields, and push forward where most people would have stopped. That kind of determination is rare, and it's what we look for in founders." Determination got the company funded. Only trial data gets it believed.

The Numbers

  • Founded: 2026 by Paul Conyngham, following Rosie's treatment; headquarters listed as San Francisco, California in the company's Y Combinator profile; Y Combinator Summer 2026 batch
  • Funding: $4 million seed round, announced August 17, 2026, led by Founders Fund, with participation from Celine Halioua of Loyal, Steve Eidelman of Modern Animal, Arash Ferdowsi of Dropbox and Gokul Rajaram, plus Y Combinator backing
  • The founding case: Rosie, an eight year old Staffordshire bull terrier cross, diagnosed with mast cell cancer in May 2024; surgery, chemotherapy and immunotherapy failed before the vaccine
  • Cost of the original work: about $3,000 paid by Conyngham for tumor and healthy DNA sequencing at UNSW, according to reporting on the case
  • Treatment timeline: first vaccine dose December 2025 in Queensland, booster the following month; several tumors shrank significantly; the company cites a roughly 75 percent tumor reduction in that single case, with its own caveat that results may vary
  • Outcome: Rosie entered remission, then her cancer returned following a later surgery, according to the company's launch announcement; no outcome data across multiple animals have been published, and nothing the company offers is approved
  • Turnaround claim: about four weeks from case to finished vaccine, based on the single founding case, according to reporting on the company's site; commercial pricing not publicly disclosed
  • Clinical studies: underway in eastern Australia with UNSW, the University of Queensland and the Garvan Institute of Medical Research; trial dogs receive the investigational vaccine at no cost
  • US status: no US product; the company says it is working with regulators on a USDA pathway for a patient specific veterinary biologic
  • The market context: cancer is the leading cause of death in dogs, per the company; about 1 in 4 dogs develops cancer in their lifetime, per AVMA and Veterinary Cancer Society figures cited in coverage; more than 1,600 oncology therapeutics and vaccines are in development worldwide, per the company
  • The field: Torigen has treated roughly 2,000 animals since 2017; in human medicine, Moderna and Merck's personalized mRNA candidate cut melanoma recurrence or death risk by 44 percent in a randomized trial (Merck, 2022)

What It Means For You

If you are a veterinary oncologist, Gamgee is a referral and evidence question arriving in your inbox soon. Owners will bring you the viral version of Rosie's story. Your job is the unviral version: one uncontrolled case, concurrent treatments, an undisclosed tumor grade, a remission and then a recurrence. Practices that prepare that honest explanation now, and track the Australian study's eligibility and readout, will be the trusted voice when clients ask whether a made for one dog vaccine is right for their dog.

If you run a general practice, notice the workflow pitch. Gamgee wants intake, tissue collection, treatment and monitoring to run through ordinary clinics with minimal added chair time, while sequencing, design and manufacturing stay centralized. That is the distribution logic every successful veterinary platform of the last decade has used: the specialist science stays central, the client relationship stays local. Whether the four week turnaround holds outside a single case is the operational fact to verify before you build any client expectation around it.

If you build or fund in pet health, Gamgee is a clean test of the biology thesis that dominated 2026 pet venture funding. The seed is small, the claims are large, and the gap between them is a clinical study that has not read out. The diligence questions are specific: how many dogs are enrolled, what tumor types and grades, what endpoints, who manufactures at GMP standard, and what does the USDA say about licensing a vaccine that is different for every patient. A company that answers those questions with documents, not story, is a company. One that answers with Rosie is still a story.

And if you compete in pet oncology or advanced therapeutics, do not dismiss this as a $4 million seed. Sequencing, AI target selection and mRNA manufacturing have become cheap enough for an outsider with no biology training to assemble them into a treatment with academic partners. Your moat is no longer the technology stack. It is evidence, regulatory standing, manufacturing reliability and oncologist trust, and Gamgee has to earn all four in public.

What To Watch

Watch the Australian studies for the only numbers that will settle this: enrollment counts, tumor types, response rates across many dogs, and duration of response. A second Rosie proves nothing. Twenty dogs with published outcomes, including the non responders, would change the conversation entirely.

Watch the USDA pathway. A patient specific biologic, manufactured differently for every patient, does not fit the standard licensing template built for identical vials. How the Center for Veterinary Biologics handles that question will matter far beyond Gamgee: Torigen's history shows a company having to change regulatory classifications as the framework shifted, and every personalized therapy in veterinary medicine is watching the same door.

Watch the turnaround and the price. The company talks about a vaccine in about four weeks, based on one case, and has not disclosed commercial pricing. Personalized manufacturing lives or dies on whether that timeline, and a price an owner can actually pay, survive contact with volume. Until Gamgee publishes either number with real cases behind it, both are claims.

Watch who signs on. The company says it is recruiting veterinary oncologists and trial partners. Named oncology groups enrolling patients, and academic partners publishing protocols, are the credibility milestones to count, not social media reach.

Finally, watch how the company talks about Rosie. So far it has done the rare thing: its own launch announcement states the remission and the recurrence in the same breath, and its site carries the single case caveat on its headline figure. If that honesty survives the pressure to fundraise and sell, Gamgee will be an unusually trustworthy young biotech. If the recurrence quietly disappears from the pitch, you will have learned something else about it, earlier than the trial data could teach you.

Sources

  • Gamgee, "One Dog's Legacy Becomes GAMGEE," launch announcement, GlobeNewswire, August 17, 2026: https://aapnews.aap.com.au/aapreleases/globenewswire9811478
  • Y Combinator, Gamgee company profile (Summer 2026, San Francisco; platform description and Rosie case summary): https://www.ycombinator.com/companies/industry/drug-discovery-and-delivery
  • Medical Daily, "Rosie's Cancer Came Back After Her AI-Designed Vaccine, and Her Owner Just Raised $4 Million," August 18, 2026: https://www.medicaldaily.com/rosie-dog-ai-mrna-cancer-vaccine-gamgee-launch-477500
  • PYMNTS, "One Dog's Cancer Vaccine Just Became a Real Company," August 13, 2026: https://www.pymnts.com/news/artificial-intelligence/2026/one-dogs-cancer-vaccine-just-became-a-real-company/
  • R&D World, "ChatGPT, mRNA and a dog named Rosie: Torigen CEO on what the viral cancer story reveals about pet immunotherapy," 2026: https://www.rdworldonline.com/chatgpt-mrna-and-a-dog-named-rosie-torigen-ceo-on-what-the-viral-cancer-story-reveals-about-pet-immunotherapy/
  • Gamgee official site and share image, gamgee.io: https://gamgee.io
  • The Underbite, "Pet Venture Money Moved to Drugs and Diagnostics in 2026," via Good Company, November 13, 2026: https://goodcompany.pet/story/pet-venture-money-moves-biology